Zhongzhi Pharmaceutical ( 03737.HK ) Parent company's attributable profit for 2025 decreased by approximately 81.8% to 17.3 million yuan

NightAirdropper · 2026-03-28T19:47:26+00:00

Zhongzhi Pharmaceutical announced that its revenue in 2025 is approximately 1.738 billion yuan, a year-on-year decrease of 21.6%, with the parent company's profit dropping 81.8% to 17.3 million yuan. The company plans to improve performance by expanding sales channels and implementing digital management, expecting future operational conditions to improve.

NightAirdropper

2026-03-28 19:47:26

Abstract generation in progress

Glory Financial March 26丨China Intelligent Pharmaceutical (03737.HK) announced that, for the year ending December 31, 2025, the group’s main business will still be engaged in pharmaceuticals in China and operating chain pharmacies in Guangdong Province, China. The group’s revenue decreased by approximately 21.6% to about RMB 1.738 billion. Profit attributable to the parent company’s owners fell by approximately 81.8% to RMB 17.3 million. Earnings per share are RMB 0.02.

In 2026, the company will enhance its market share by increasing efforts to develop secondary and tertiary terminal channels, and will save operating costs through the implementation of digital management, in order to achieve a business strategy focused on expanding income and reducing expenses while solidifying its foundation and breaking through channels for development. With the recovery of the consumer market, more digestion of existing inventory, and adjustments and optimizations in business operations, the company’s operational performance will continue to improve.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

2 Likes